Chief Executive Officer/Chief Commercial Officer
Andrew joined Immunocore as Chief Commercial Officer in October 2017. He has more than 30 years of experience in the pharmaceutical sector and has held numerous cross-functional roles spanning sales, marketing, corporate strategy, commercial strategy, country management, business development and regional leadership. Andrew joined Immunocore from Eli Lilly & Co, where he served in a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology, President Biomedicines Business Unit, Australia, Canada and Europe and Snr VP Digital Ventures.
Andrew has also served as Chairman of the European Markets Committee at EFPIA. He received his degree in Biochemistry from Cardiff University.
Chief Scientific Officer
Bent co-founded Immunocore in 2008 and has served as Chief Scientific Officer and Executive Board Member since that time. He is also scientific co-founder of Adaptimmune Ltd, where he provides strategic and advisory input as well as oversight of research programmes. He was previously Chief Scientific Officer of Avidex, a company he founded in 1999 as a spin-out from the University of Oxford to develop novel T cell receptor-based drugs. Bent was head of the Immune Receptor Group at the Institute of Molecular Medicine (IMM) in Oxford from 1993 to July 2000. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark, and undertook post-doctoral research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. Bent has authored numerous scientific papers and is considered a world expert in the field of T cell receptor immunology. In 2015, he was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.
Chief Financial Officer
Paul joined Immunocore as Chief Financial Officer in January 2017. He has over 25 years’ experience in the life sciences and telecommunications sectors. Mr Fry spent more than 25 years at GlaxoSmithKline (GSK), serving in a number of roles including as Chief Financial Officer for GSK’s Italian Pharmaceutical business and as Head of Global Drug Discovery Finance in R&D. More recently he oversaw the financial aspects of GSK’s recent multibillion dollar 3-part transaction with Novartis. Prior to joining Immunocore Paul served as Director of Global Finance Operations at Vodafone plc, where he was responsible for the global delivery of Vodafone’s core financial processes as well as large transformation projects and programmes. He holds a BA Hons degree in Philosophy, Politics and Economics (PPE) from the University of Oxford.
Chief People Officer
Samantha joined Immunocore as Chief People Officer in September 2017. She has more than 17 years’ experience in Human Resources, providing talent solutions to senior leaders within the biopharmaceutical and manufacturing industries, with expertise in leadership coaching and culture development. Prior to joining Immunocore, Samantha spent 10 years at UCB as UK HR Director and Global HR Business Partner for the New Medicines division and later as Global Talent Solutions Partner for the global Neurology business unit. While at UCB, Samantha led the development of global talent strategies and delivered several large transformational change programmes. Samantha is a Fellow of the Chartered Institute of Personnel and Development (FCIPD), and is a qualified leadership coach.
Chief Development Officer
James joined Immunocore in December 2015 as Chief Development Officer. James has more than 25 years of experience in the pharmaceutical and biotechnology industries covering a range of development phases and therapeutic areas, including oncology. Most recently he was Chief Development Officer at Creabilis. Prior to this, James held various senior positions at Pfizer Inc., including Head of European and Asian Development Operations, Development Team Leader within the Gastrointestinal Therapeutic Area and Development Operations Oncology Therapeutic Area Head, Europe, where he supported the successful Aromacin® EU filing and approval and has led the delivery of several global drug filings. He holds an M.Phil from Imperial College London in Statistics and Operational research.